Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Genzyme Expects Shortage of Thyrogen Medicine in U.S., Europe

Don't Miss Out —
Follow us on:

March 18 (Bloomberg) -- Genzyme Corp. said it expects a shortage of its thyroid medicine Thyrogen because of a manufacturing issue.

The Cambridge, Massachusetts-based company said in a statement on its website today that it is warning doctors to prepare for a shortage of Thyrogen in the U.S. from mid-April to Mid-June. The European Medicines Agency also said today it was informed by Genzyme of a possible supply shortage. The global supply is expected to fluctuate through July, Genzyme said.

Thyrogen, used in the treatment of thyroid cancer, had sales of $182 million last year, or 4.5 percent of Genzyme’s revenue. The shortage won’t be material to earnings, according to Erin Emlock, a company spokeswoman. Genzyme is being acquired by Paris-based Sanofi-Aventis SA.

To contact the reporters on this story: Kristen Hallam in London at; Catherine Larkin in Washington at

To contact the editor responsible for this story: Adriel Bettelheim at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.